Author: ELI LILLY AND COMPANY

Posted Date:

June 8, 2026

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

ELI LILLY AND COMPANY

June 8, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

ELI LILLY AND COMPANY

June 8, 2026
Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

ELI LILLY AND COMPANY

June 8, 2026
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

ELI LILLY AND COMPANY

June 2, 2026
Lilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

ELI LILLY AND COMPANY

May 31, 2026
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association’s 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

ELI LILLY AND COMPANY

May 28, 2026
Foundayo and Zepbound now covered for millions of Americans

ELI LILLY AND COMPANY

May 28, 2026
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference

ELI LILLY AND COMPANY

May 27, 2026
Lilly announces three acquisitions to build infectious disease portfolio

ELI LILLY AND COMPANY

May 26, 2026
A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

ELI LILLY AND COMPANY

May 25, 2026